JP2010501595A5 - - Google Patents

Download PDF

Info

Publication number
JP2010501595A5
JP2010501595A5 JP2009525861A JP2009525861A JP2010501595A5 JP 2010501595 A5 JP2010501595 A5 JP 2010501595A5 JP 2009525861 A JP2009525861 A JP 2009525861A JP 2009525861 A JP2009525861 A JP 2009525861A JP 2010501595 A5 JP2010501595 A5 JP 2010501595A5
Authority
JP
Japan
Prior art keywords
composition
antigen
inducing
adjuvant
adjuvants
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009525861A
Other languages
English (en)
Japanese (ja)
Other versions
JP5265545B2 (ja
JP2010501595A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2007/001277 external-priority patent/WO2008025095A1/en
Publication of JP2010501595A publication Critical patent/JP2010501595A/ja
Publication of JP2010501595A5 publication Critical patent/JP2010501595A5/ja
Application granted granted Critical
Publication of JP5265545B2 publication Critical patent/JP5265545B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009525861A 2006-09-01 2007-08-31 免疫応答を誘発または誘導する方法 Expired - Fee Related JP5265545B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2006904796 2006-09-01
AU2006904796A AU2006904796A0 (en) 2006-09-01 Method of Eliciting or Inducing an Immune Response
PCT/AU2007/001277 WO2008025095A1 (en) 2006-09-01 2007-08-31 Method of eliciting or inducing an immune response

Publications (3)

Publication Number Publication Date
JP2010501595A JP2010501595A (ja) 2010-01-21
JP2010501595A5 true JP2010501595A5 (https=) 2010-09-16
JP5265545B2 JP5265545B2 (ja) 2013-08-14

Family

ID=39135429

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009525861A Expired - Fee Related JP5265545B2 (ja) 2006-09-01 2007-08-31 免疫応答を誘発または誘導する方法

Country Status (11)

Country Link
US (1) US9150619B2 (https=)
EP (1) EP2066341B1 (https=)
JP (1) JP5265545B2 (https=)
KR (1) KR20090064412A (https=)
CN (1) CN101522213A (https=)
AU (1) AU2007291887B2 (https=)
CA (1) CA2662164A1 (https=)
DK (1) DK2066341T3 (https=)
ES (1) ES2547855T3 (https=)
NZ (1) NZ575141A (https=)
WO (1) WO2008025095A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1239876B1 (en) * 1999-11-19 2008-07-30 Csl Limited Hcv vaccine compositions
NZ583377A (en) * 2007-10-12 2013-11-29 Csl Ltd Method of eliciting an immune response against pandemic influenza virus
CA2780207A1 (en) * 2009-11-18 2011-05-26 Auburn University Low antigen-dose immunization for maximizing t-helper cell 1 (th1) immunity against disease
KR102314245B1 (ko) * 2012-03-27 2021-10-20 배리에이션 바이오테크놀로지스 아이엔씨. 항-사이토메갈로바이러스 중화 항체를 탐지하기 위한 방법
CA3069259A1 (en) * 2017-07-27 2019-01-31 Medi-Immune Limited Vaccine compositions
GB2564901B (en) * 2017-07-27 2020-04-08 Medi Immune Ltd Vaccine compositions

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
CA2323733A1 (en) * 1998-04-13 1999-10-21 Michael B. Brenner Vaccine compositions comprising cd-1 antigens and t-cell stimulating compound and methods of use thereof
EP0976403A1 (en) * 1998-07-30 2000-02-02 Stichting Instituut voor Dierhouderij en Diergezondheid (ID-DLO) Adjuvant comprising pulmonary surfactant
DE60025019T2 (de) * 1999-10-29 2006-08-24 Nektar Therapeutics, San Carlos Trockenpulverzusammensetzungen mit verbesserter dispersivität
AU2001251316A1 (en) * 2000-04-04 2001-10-15 Antigenics Inc. Isolated and purified nonpeptide antigens from mycobacterium tuberculosis
WO2001095934A2 (en) 2000-06-16 2001-12-20 Sembiosys Genetics Inc. The use of plant oil-bodies in vaccine delivery systems
GB0021757D0 (en) 2000-09-04 2000-10-18 Colaco Camilo Vaccine against microbial pathogens
DE10044622A1 (de) * 2000-09-09 2002-03-21 Krupp Corpoplast Maschb Gmbh Vorrichtung zur Herstellung von Vorformlingen
US20030190333A1 (en) * 2002-02-04 2003-10-09 Corixa Corporation Immunostimulant compositions comprising aminoalkyl glucosaminide phosphates and saponins
GB0401239D0 (en) 2004-01-21 2004-02-25 Molecularnature Ltd Adjuvant compositions
TWI277032B (en) * 2004-02-27 2007-03-21 Au Optronics Corp Planar display module
CA2565859A1 (en) 2004-05-07 2005-11-24 President And Fellows Of Harvard College Pulmonary malarial vaccine

Similar Documents

Publication Publication Date Title
Wang et al. New technologies in developing recombinant attenuated Salmonella vaccine vectors
JP2010501595A5 (https=)
JP2015524462A5 (https=)
WO2010037395A3 (en) Mhc multimers in cancer vaccines and immune monitoring
WO2009089535A3 (en) Polypeptide vaccine and vaccination strategy against mycobacterium
JP2011518170A5 (https=)
HRP20160816T1 (hr) Upotreba virusa influence i emulzije ulja u vodi kao adjuvansa radi poticanja t-stanica cd4 i/ili poboljšanog odgovora memorijskih b-stanica
NZ711518A (en) Multivalent glycoconjugate vaccines
WO2009039854A8 (en) Mhc multimers in tuberculosis diagnostics, vaccine and therapeutics
JP2008505857A5 (https=)
RU2017137357A (ru) Быстрорастворяющаяся лекарственная форма пероральной вакцины, в которой используют крахмал
WO2009060281A3 (en) Immune stimulatory oligoribonucleotide analogs containing modified oligophosphate moieties
HRP20150177T1 (hr) Cjepivo protiv tuberkuloze i postupak upotrebe tog cjepiva
WO2008054535A3 (en) Novel influenza m2 vaccines
WO2013082535A3 (en) Controlled-release peptide compositions and uses thereof
WO2007146359A3 (en) Sea lice antigen vaccines
JP2008539169A5 (https=)
WO2008028667A3 (en) Use of glycolipids as adjuvants
WO2005056769A3 (en) Orally-administered live bacterial vaccines for plague
JP2016513537A5 (https=)
JP2018043942A5 (https=)
ES2436344B1 (es) Composición farmacéutica de diacetilmorfina y naloxona para administración oral
Yao et al. SOCS1 and SOCS3 are targeted by hepatitis C virus core/gC1qR ligation to inhibit T-cell function
HK1141793A (en) Cationic lipids compositions and methods for enhancing immune responses to vaccines
CN302498376S (zh) 中医封包综合治疗仪(ab3型)